

3-22-2021

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

Ida E. Sønderby

Dennis van der Meer

Clara Moreau

Tobias Kaufmann

G. Bragi Walters

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Sønderby, I.E., van der Meer, D., Moreau, C. et al. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans. *Transl Psychiatry* 11, 182 (2021). <https://doi.org/10.1038/s41398-021-01213-0>

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.

Authors

Ida E. Sønderby, Dennis van der Meer, Clara Moreau, Tobias Kaufmann, G. Bragi Walters, Maria Ellegaard, Nicholas B. Blackburn, John Blangero, Joanne E. Curran, and Juan M. Peralta

ARTICLE

Open Access

1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

Abstract

Low-frequency 1q21.1 distal deletion and duplication copy number variant (CNV) carriers are predisposed to multiple neurodevelopmental disorders, including schizophrenia, autism and intellectual disability. Human carriers display a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively. The underlying brain structural diversity remains largely unknown. We systematically called CNVs in 38 cohorts from the large-scale ENIGMA-CNV collaboration and the UK Biobank and identified 28 1q21.1 distal deletion and 22 duplication carriers and 37,088 non-carriers (48% male) derived from 15 distinct magnetic resonance imaging scanner sites. With standardized methods, we compared subcortical and cortical brain measures (all) and cognitive performance (UK Biobank only) between carrier groups also testing for mediation of brain structure on cognition. We identified positive dosage effects of copy number on intracranial volume (ICV) and total cortical surface area, with the largest effects in frontal and cingulate cortices, and negative dosage effects on caudate and hippocampal volumes. The carriers displayed distinct cognitive deficit profiles in cognitive tasks from the UK Biobank with intermediate decreases in duplication carriers and somewhat larger in deletion carriers—the latter potentially mediated by ICV or cortical surface area. These results shed light on pathobiological mechanisms of neurodevelopmental disorders, by demonstrating gene dose effect on specific brain structures and effect on cognitive function.

Introduction

Inter-individual differences in brain structure are highly heritable¹, but identifying the genes that contribute to brain development is challenging. Genome-wide association studies (GWAS) of brain anatomical structures indicate the influence of many single-nucleotide polymorphisms (SNPs) with small effect sizes^{2,3}, but the links to brain function remain weak. Evidence is emerging that some rare copy number variants (CNVs)—that is, regions of the genome that are either deleted or duplicated—are associated with both substantial brain size and shape differences; for example, the 7q11.23^{4,5}, 22q11.2^{6,7}, 15q11.2^{8–11} and 16p11.2 proximal^{12–14} and distal CNVs¹⁵. Many of these CNVs also have a wide-ranging phenotypic impact, including poorer cognitive abilities^{8,16–18} and increased risk of

neurological or neurodevelopmental disorders. The strong impact of these CNVs on brain structure and behaviour make them valuable for studies of the molecular mechanisms contributing to aberrant human neurodevelopment.

The 1q21.1 distal CNV has a known large effect on head circumference, as evident from a high prevalence of micro- and macrocephaly in deletion and duplication carriers, respectively^{19–21}. This, along with its position in a region that is rich in genes unique to the human lineage (i.e. absent in primates)^{22,23}, makes the 1q21.1 distal CNV particularly interesting for the study of aberrations in human brain structure. However, its relatively low frequency, 1 in ~3400 (deletions) and 1 in 2100 (duplications)^{8,16}, has hampered the study of its effects on brain structure.

1q21.1 distal deletion and duplication carriers are both at higher risk for several neurodevelopmental disorders including schizophrenia^{24,25}, intellectual disability (ID), developmental delay, speech problems, autism spectrum

Correspondence: Ida E. Sønderby (i.e.sonderby@medisin.uio.no)
Full list of author information is available at the end of the article.

© The Author(s) 2021



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

disorders, motor impairment^{19,26–28} and epilepsy^{26,29}, in addition to the separate risk for the duplication carriers for ADHD³⁰, bipolar disorder and major depression^{31,32}. Further, general cognitive ability (IQ) was lower in carriers in a small clinical study¹⁹ and in the UK Biobank³³. In addition, 1q21.1 distal CNVs display a positive dose response on head circumference^{19–21}, height and weight^{34,35} and are associated with various somatic diseases and traits, including bone and muscle deviations³⁴ and cataract³⁶ (deletion only), diabetes³⁶ (duplication only) and heart disease^{36–39} (both). Conversely, several studies report carriers without any clinically evident phenotypes^{19,38} and considerable heterogeneity^{40,41}, suggesting incomplete penetrance and variable expressivity. The Df(h1q21)+/– mouse, deleted in the syntenic 1q21.1 distal region, displays some phenotypes similar to human CNV carriers, including reduced head-to-tail length and altered dopamine transmission in response to psychostimulants, as seen in people with schizophrenia⁴².

The 1q21 region in humans is rich in low copy number repeats^{20,43} and contains several recurrent CNVs with differing breakpoints^{21,37}. Thus, gene estimates vary, but the core interval encompasses at least 12 protein-coding genes including several human-specific genes such as *HYDIN2*^{21,37}, *NOTCH2NLS*^{22,23} and the DUF1220/Olduvain domain-containing *NBPF*-encoding genes^{44–46}—the two latter were recently shown to have evolved as a two-gene unit⁴⁷. Particularly interesting in the context of brain development are the recently characterized *NOTCH2NL* genes, absent in human's closest living relatives and shown to prolong cortical neurogenesis^{22,23}.

Despite the strong effects on neurodevelopmental traits and disorders, the impact of the 1q21.1 CNVs on human brain structure is largely unknown. Here, we present the first large-scale systematic neuroimaging study of 1q21.1 distal CNV carriers, investigating brain structure in >37,000 individuals including 28 deletion and 22 duplication carriers. We mapped the effect of the 1q21.1 distal CNV on subcortical volumes, intracranial volume (ICV) and global and regional measures of mean cortical thickness and surface area. We investigated variation in cognitive task performance and supplemented with exploratory mediation analysis of the brain on cognition in the UK Biobank. Given prior findings^{19–21,48}, we explored a dose-dependent effect of copy number on brain structures and decreased cognitive performance for both 1q21.1 distal deletion and duplication carriers in comparison to non-carriers.

Materials and methods

Sample description

The brain structural sample comprises a total of 39 cohorts with genotyping and magnetic resonance imaging (MRI) data—38 from the ENIGMA-CNV consortium in

addition to a subsample of the UK Biobank⁴⁹ (project ID #27412). Demographic characteristics for each cohort are described in Supplementary Table 1 with a reference to participants' collection and datasets including individual inclusion and exclusion parameters. Extended information on diagnosis and family information can be found in Supplementary Note 1 and age distribution of the cohorts in Supplementary Fig. 1. All participants gave written informed consent and sites involved obtained ethical approvals. The main 1q21.1 distal sample consisted of 28 deletion carriers, 22 duplication carriers and 37,088 non-carriers (Table 1) from 13 different datasets and 15 scanner sites with various ascertainment (family, clinical and population studies, case–control study for psychiatric disease) collected up until 30 September 2019. Non-carriers were defined as having no CNVs known to cause neurodevelopmental diseases (as defined in Supplementary Table 2). In the meta-analysis, an independent Icelandic sample from deCODE Genetics consisting of two deletion carriers and five duplication carriers in addition to 1150 non-carriers was added.

Genotyping and QC

The genotypes were obtained by genotyping with commercially available platforms, performed at participating sites for each cohort (Supplementary Table 1). Individuals were excluded exclusively based on quality control (QC) parameters from the CNV calling. No exclusion was done due to ancestry in the primary analysis, but the effect of ancestry was evaluated in a separate analysis (see below).

CNV calls and validation in the core ENIGMA-CNV sample

Almost all cohorts had CNVs called and identified in a unified manner as described previously¹⁵. In brief, CNVs were called using PennCNV⁵⁰ and appropriate population frequency (PFB) files and GC (content) model files (Supplementary Table 3 and Supplementary Notes 2 and 3). Samples were filtered and CNVs identified based on standardized QC metrics¹⁵ (Supplementary Notes 2 and 3). The 1q21.1 distal region was well covered by all arrays (Supplementary Fig. 2). CNVs overlapping the region of interest (1q21.1 distal and 1q21.1 distal and proximal) were identified with the R package iPsychCNV, visualized and manually inspected.

Image acquisition and processing

All brain measures were obtained from structural T1-weighted MRI data collected at participating sites around the world and analysed with the standardized image analysis, FreeSurfer, quality assurance and statistical methods as per the harmonized neuroimaging protocols developed within ENIGMA2³ and ENIGMA3 (<http://enigma.ini.usc.edu/protocols/imaging-protocols/>). Further detail on data

Table 1 Demographic data.

	ENIGMA-CNV				deCODE			
	del	nc	dup	<i>P</i>	del	nc	dup	<i>P</i>
<i>n</i>	28	37,088	22		2	1150	5	
Sex, male (%)	15 (54%)	17,912 (48%)	9 (41%)		1 (50%)	511 (44%)	2 (33%)	
Age (mean (SD))	41.7 (19.0)	61.1 (12.8)	55.4 (12.7)	<0.001	53.5 (2.1)	44.8 (12.4)	46.4 (16.5)	
Children (age <18 years)	4 (14%)	665 (1.8%)		<0.001	0	0	0	
Known diagnosis (%)	11 (39.3%)	2424 (6.5%)	7 (32%)	<0.001		238 (21%)	2 (40%)	
Disease type (%)								
ADHD		1 (~0%)				181 (16%)	2 (40%)	
Autism						2 (0.2%)		
Bipolar disorder						7 (0.6%)		
Clinically recruited (no diagnosis)	6 (21.4%)		4 (18%)					
Dyslexia	1 (3.6 %)							
F-ICD-10 diagnosis (UK Biobank)		858 (2.3%)	1 (4%)					
G-ICD10 diagnosis (UK Biobank)	1 (3.0%)	1439 (3.8%)	1 (4%)					
MDD		1 (~0%)						
Multiple diagnoses ^a	2 (7.2%)		1 (4.5%)					
Persistent depressive disorder		1 (~0%)						
SCZ	1 (3.6)	124 (0.3)				48 (4.2%)		
Scanner sites	11	15	8		2	2	1	
Datasets	9	13	7		1	1	1	

ADHD attention deficit disorder, clinically recruited in clinical NDD study but without a diagnosis, MDD major depressive disorder, SCZ schizophrenia, del deletion carrier, nc non-carriers, dup duplication carrier, *P* *P* value, AvPD avoidant personality disorder, OCD obsessive-compulsive disorder, DPD dependent personality disorder, STPD schizotypal personality disorder, NS non-significant.

P value is based on a χ^2 test for categorical values and ANOVA for continuous values.

^aFirst deletion carrier: agoraphobia, AvPD, OCD, DPD, other substance-related disorder, conduct disorder. Second deletion carrier: specific phobia, social phobia, MDD, AvPD, STPD. Duplication carrier: social phobia, OCD, MDD, AvPD.

processing is provided in Supplementary Note 4. Details on study, scanner, vendor, field strength, sequence, acquisition parameters and FreeSurfer versions used are outlined in Supplementary Table 4.

Statistical analysis

Imaging data processing and CNV calling were performed locally and de-identified CNV and imaging data were provided for a central mega-analysis. One of a pair of duplicates was kept. Relatives were removed from the sample used for the main analysis. In addition, we conducted a number of sensitivity analyses to test the robustness of the results (Supplementary Note 5 and Supplementary Tables 5–8). Individuals with a minimum overlap of 0.4 to regions with known pathogenic CNVs (Supplementary Table 2) were excluded from the analysis regardless of copy number status as were individuals from scanner sites without 1q21.1 distal CNV carriers.

Brain measures were normalized in R v3.3.2 by an inverse normal transformation of the residual of a linear regression on the phenotype correcting for covariates as done previously¹⁵. For the primary analysis, covariates were age, age², sex, scanner site and ICV. In the analysis of ICV, ICV was not included as a covariate. These final covariance-corrected values were used in downstream analysis and are reported for each measure. For comparison between groups, normalization was carried out including only the groups addressed (deletion and non-carriers, duplications and non-carriers) except for the deletion versus duplication comparison, where values from normalization of the entire dataset were used due to the low numbers.

For the copy number dosage effect analysis (i.e. the effect on brain structure of 1q21.1 distal copy number variation), a linear regression on the copy number status of the individuals (deletion = 1, normal = 2, duplication = 3) was performed using the following model: covariance-corrected,

normalized brain measure \sim copy number (deletion = 1, non-carrier = 2, duplication = 3). For comparison between groups, a two-sample, two-sided t test assuming equal variance in all carrier/non-carrier groups was employed (R v3.3.2) where deletion or duplication carriers were compared either to each other or to non-carriers. To correct for the multiple comparisons, we calculated the number of independent outcome measures through the spectral decomposition of a correlation matrix using MatSpDlite (<https://neurogenetics.qimrberghofer.edu.au/matSpDlite/>) of the three global, seven subcortical and 68 regional cortical measures. Based on the ratio of observed eigenvalue variance to its theoretical maximum, the estimated equivalent of independent measures was 36. Thus, we set the significance threshold at $\alpha = 0.05/36 = 0.0014$. We report the uncorrected P values throughout the manuscript.

Effect size is calculated as the absolute effect size (the difference in mean between the two copy number groups in the t test—which, in this case, equals Cohen's D as the standard deviation of the normalized brain measures is one) and the estimate of beta in the linear regression. Plots were generated using R library ggplot2 v2.2.1⁵¹. Regional cortical visualization was done with the R package ggseg v1.5.1.

In a novel analysis, the independent Icelandic data were processed and analysed as the main dataset. We meta-analysed the results using the R package *metafor* v2.0.0, as previously¹⁵.

Cognitive task performance data

We downloaded behavioural performance measures on seven cognitive tests (the pairs matching task, the reaction time task, reasoning and problem-solving tests, the digit span test, the symbol digit substitution test and the trail making A and B tests) from the UK Biobank repository, performed by at least 10% of the participants. The results were processed following the general approach by Kendall et al.¹⁶. For more details, see Supplementary Note 6. For the analysis of the seven cognitive measures, we set the significance threshold to $\alpha = 0.05/7 = 0.007$.

Mediation analysis

Mediation analyses were done with the R package *mediation* v4.4.7. Brain measures were normalized as described above and cognitive tasks were corrected for age, age² and sex prior to input into the analysis. We report the proportion of the total effect of the CNV on cognitive task performance mediated by the brain measures ('path ab'/'path c'), with P values calculated through quasi-Bayesian approximation using 5000 simulations. We set the significance threshold at $\alpha = 0.05/(2 + 4) \times 6 = 1.4 \times 10^{-3}$ given the test of two structures for deletion and four for duplication carriers on six

cognitive tests. The digit span test was excluded since no 1q21.1 CNV carriers had results from both this cognitive test and brain structural data.

Results

Sample characteristics

The main 1q21.1 distal (146.5–147.4 Mb, hg19) brain structural dataset consisted of 28 deletion and 22 duplication carriers and 37,088 non-carriers (derived from the same scanner sites as the CNV carriers) from ENIGMA-CNV and UK Biobank (Table 1, separate demographics in Supplementary Table 9). The age of CNV carriers was lower (41.7 ± 19.0 (deletions), 55.4 ± 12.7 (duplications), respectively) than that of non-carriers (61.1 ± 12.1) (Table 1). Eleven deletion carriers and seven duplication carriers had a known neurological, neurodevelopmental or psychiatric diagnosis or had been recruited in a clinical CNV study. The remaining carriers either did not have an established diagnosis or were recruited in studies from which diagnostic information was unavailable (Table 1 and Supplementary Table 10). Of the 37,088 non-carriers, 6.5% (2425) had an established neurological, neurodevelopmental or psychiatric disorder.

1q21.1 distal CNV associated with global cortical surface structures

For our main dataset, there was a significant positive association between the number of 1q21.1 distal copies and ICV ($\beta = 1.47$, $P = 2.8 \times 10^{-25}$) as well as cortical surface area ($\beta = 0.81$, $P = 1.1 \times 10^{-8}$) (Fig. 1 and Supplementary Table 5) at a significance threshold of $P < 0.0014$ after correction for age, age², sex, scanner site and ICV. In contrast, a significant negative copy number dosage effect was identified for the caudate ($\beta = -0.49$, $P = 6.9 \times 10^{-4}$) and hippocampal volumes ($\beta = -0.56$, $P = 1.3 \times 10^{-4}$). T tests indicated a decrease in ICV (Cohen's $D = -1.84$ (−17%), $P = 1.6 \times 10^{-22}$) for deletion carriers and an increase for duplication carriers (Cohen's $D = 0.90$ (+10%), $P = 2.3 \times 10^{-5}$), respectively, compared to non-carriers (Supplementary Table 6). For a raw value plot of ICV, see Supplementary Fig. 3. The cortical surface area dosage effect was primarily driven by the deletion carriers with a significantly lower total cortical surface area (Cohen's $D = -1.13$ (−23%), $P = 2.1 \times 10^{-9}$) and the dosage effect on caudate and hippocampus was primarily driven by duplication carriers with significantly smaller caudate (Cohen's $D = -0.71$ (−16%), $P = 0.0012$) and hippocampal (Cohen's $D = -0.92$ (−15%), $P = 4.1 \times 10^{-5}$) volumes than non-carriers (Fig. 1 and Supplementary Table 7). Adding an independent Icelandic dataset with two deletions, five duplications and 1150 non-carriers (Table 1) in a meta-analysis strengthened the majority of the dosage results (Supplementary Fig. 4 and Supplementary Tables 11 and 12)




Fig. 1 Cortical surface area and ICV show a positive dosage effect and caudate and hippocampus a negative dosage effect to copy number in the 1q21.1 distal region in our main sample (ENIGMA-CNV and UK Biobank). Boxplots of subcortical volumes, cortical surface area and mean cortical thickness and ICV are shown. Deletion carriers (del) in red, non-carriers (nc) in grey and duplication carriers (dup) in blue, respectively. The normalized brain values are presented. Boxplots represent the mean. Copy number dosage effect is noted at the bottom of each panel. Significant differences after correction between groups are noted as * $P < 0.0014$, ** $P < 0.00014$, *** $P = 0.000014$. Centre line represents the median, box limits are the upper and lower 25% quartiles, whiskers the 1.5 interquartile range and the points are the outliers. All analyses were corrected for age, age squared, sex, scanner site and ICV (except for ICV).

and revealed additional significant between-group differences in nucleus accumbens, caudate and putamen (Supplementary Table 12).

A number of sensitivity analyses were run on the main dataset, namely:

- (a) Matching each carrier with one non-carrier for age, sex, scanner site and ICV or age, sex, scanner site;
- (b) including only: (i) non-affected individuals (i.e. excluding individuals with a known neurodevelopmental or neurological disorder




Fig. 2 Results from the t tests and linear regression of 1q21.1 copy number variation on regional cortical surface area and cortical thickness. First and third rows: Effect sizes (Cohen's d for the t tests, beta coefficient for the dosage/linear regression). Second and fourth rows: Statistical significance in $-\log_{10}$ of the P value. Significant areas in rows 1 and 3 are marked with black lines with increasing thickness for increasing significance ($P < 0.0014$). The column names indicate the comparisons with del = deletion carriers, nc = non-carriers, dup = duplication carriers. All measures were corrected for age, age², sex, scanner site and ICV.

- diagnosis; (ii) adults (age ≥ 18); (iii) non-affected adults; (iv) children (age < 18); (v) ENIGMA-CNV or (vi) UK Biobank;
- (c) controlling for ancestry;
- (d) excluding ICV as a covariate or;
- (e) including first- and second-degree relatives (see Supplementary Note 5 for methods).

These analyses validated the overall effects (Supplementary Tables 5 and 6).

The 1q21.1 distal CNV is associated with regional brain structures

The largest dosage effects for the regional cortical surface area were found in the frontal lobes followed by the cingulate cortex—with additional significant effects in three regions of the parietal and temporal lobes (Fig. 2 and Supplementary Table 7). Likewise, through t tests, the largest effects in both deletion and duplication carriers in comparison to non-carriers were observed in the frontal and cingulate cortices (Fig. 2 and Supplementary Table 8).

For regional cortical mean thickness, we identified significant negative dosage effects in the superior temporal region and significant positive dosage effects for the pericalcarine region (Fig. 2 and Supplementary Tables 7 and 8). Similarly, significant increases in mean cortical thickness were observed in deletion carriers versus non-carriers in the pars triangularis and superior temporal

regions and a significant decrease in the pericalcarine region (Fig. 2 and Supplementary Table 8). All regional results were corrected for age, age², sex, scanner site and ICV. Sensitivity analyses similar to those performed for subcortical regions confirmed the robustness of the results (Supplementary Tables 7 and 8).

1q21.1 distal CNV associated with cognitive performance and mediation by brain structures

Deletion and duplication carriers had different cognitive profiles in comparison to non-carriers when testing for association in seven different neuropsychological tests available from the full UK Biobank sample: deletion carriers had significantly poorer performance in three tests: symbol digit substitution, trail making B and pairs matching, while duplication carriers had significantly poorer performance in two tests: reaction time and the reasoning and problem-solving task (Table 2).

Testing the effect of brain structures on cognitive tests in UK Biobank participants, larger ICV and total surface area were associated with better performance on almost all tests (Table 3 and see Supplementary Table 13 for sample size details). A larger hippocampus was associated with better performance for symbol digit substitution, trail making A and B (Table 3) and a larger caudate was associated with higher performance on the trail making A (Table 3).

Table 2 1q21.1 CNV deletion and duplication carriers show deficits in specific cognitive functions.

Test	Suggested domain	n		del vs. nc			dup vs. nc	
		del	nc	dup	Cohen's D (SE)	P	Cohen's D (SE)	P
Pairs matching	Working memory	119	468,709	186	-0.36 (0.09)	7.3E - 05**	0.03 (0.01)	0.7
Reaction time	Simple processing speed	115	464,648	181	-0.12 (0.06)	0.18	-0.23 (0.07)	2.1E - 03
Reasoning and problem solving	Fluid intelligence	29	154,490	71	-0.48 (0.19)	9.2E - 03	-0.33 (0.12)	5.3E - 03
Digit span	Numeric memory	12	47,569	27	-0.27 (0.14)	0.36	0.14 (0.07)	0.47
Symbol digit substitution	Complex processing speed	24	111,900	28	-0.78 (0.2)	1.4E - 04**	0.04 (0.02)	0.83
Trail making A	Visual attention	23	98,495	27	-0.29 (0.15)	0.16	-0.14 (0.07)	0.45
Trail making B	Visual attention	23	98,494	27	-0.87 (0.21)	3.1E - 05***	-0.19 (0.1)	0.33

n sample size, del deletion carriers, dup duplication carriers, nc non-carriers, SE standard error, P P value. Multiple comparison-corrected significant findings ($P < 0.007$) are indicated in bold and with * <0.007 , ** <0.0007 and *** <0.00007 .

Next, we tested whether the brain structures significantly associated with 1q21.1 distal CNV carriers might mediate the effect of the CNV on cognition. For two of the three tests associated with deletion carrier status, there were significant mediation effects (significance threshold 1.4×10^{-3}): cortical surface area and ICV accounted for 5 and 10%, respectively, of the poorer performance of deletion carriers on symbol digit substitution, and 7 and 17%, respectively, of their poorer performance on the trail making B test (Table 3).

Discussion

Our main finding was a significant positive dosage effect in humans of 1q21.1 distal copy number on ICV and cortical surface area, with the largest differences in frontal and cingulate cortical surface area. We also identified a significant negative dosage effect on caudate and hippocampal volumes. A number of sensitivity analyses confirmed the robustness of the results. Both 1q21.1 distal deletion and duplication carriers showed poorer cognitive performance, although on different tests, with an indication that decreased ICV/cortical surface area might mediate the effect in deletion carriers.

The 1q21.1 distal CNV causes copy dosage effect on brain structures

We found a strong effect of the 1q21.1 distal CNV on the total cortical surface area, while no overall effect on mean cortical thickness was observed. A specific increase in the size of the cortical surface area with little effect on cortical thickness is observed throughout mammalian evolution including the primate lineage leading to humans⁵². This possibly reflects that cortical thickness and surface area appear to be driven by distinct genetic processes⁵³. This pattern may be the result of an increased number of symmetric or self-renewing cell-division cycles, leading to an expansion of the neural progenitor

pool and subsequently to an increase in the number of cortical neurons—in line with the radial unit hypothesis⁵². Interestingly, although not significant, mean cortical thickness tended to decrease in deletion carriers in the frontal cortical surface areas with the highest effect sizes, resembling a pattern found in lissencephaly⁵⁴. This could suggest that large regional decreases in cortical surface area correlate inversely with mean cortical thickness.

The biomechanical forces of brain growth are thought to form the expansion of the cranium so that the skull grows in harmony with the expanding brain⁵⁵. Thus, the positive copy number dosage effect on cortical surface area may directly trigger the effect on head circumference^{19–21} and ICV of 1q21.1 distal carriers due to modifications in pressure. Altered mechanical pressure might also cause the negative copy number dosage effect on the hippocampus and caudate volumes, effects on subcortical volumes also observed in a UK Biobank exploratory study on six individuals with a 1q21.1 distal duplication⁵⁶.

Human-specific genes may affect the cortical surface area and cross-species effects

The positive copy number dosage effect on brain structure with the same direction as for weight and height^{34,35} likely results from altered gene expression as observed in 1q21.1 distal CNV cell lines⁴⁸. In an independent experiment on fetal tissue, we also observed dynamic expression patterns of the genes in the 1q21.1 interval consistent with potential roles in cortical neurogenesis and development (Supplementary Note 7 and Supplementary Figs. 5 and 6).

GWAS based on the hg19 genome assembly have not identified hits in the 1q21.1 genomic region for ICV⁵⁷, total cortical or regional surface area^{53,58}. Assembly of the 1q21.1 region⁵⁹ and thus gene discovery is complicated due to the presence of numerous low copy number repeats^{20,43} and has been faulty until the GRCh38 genome

Table 3 Mediation analysis of brain structures over the association between 1q21.1 distal CNV carrier status and performance in the cognitive tasks in the UK Biobank.

	Path B—effect of brain structure on cognition		Deletion		Duplication	
	Estimate (SE)	P	Prop. mediated	P	Prop. mediated	P
Pairs matching						
Caudate	0.0023 (0.0053)	0.66			3.5E – 03	0.85
Hippocampus	0.005 (0.0052)	0.34			9.8E – 03	0.68
SurfArea	0.031 (0.0055)	1.9E – 08	–0.07	0.65	–4.4E – 03	0.9
ICV	0.027 (0.0054)	4.3E – 07	–0.12	0.64	–0.07	0.51
Reaction time						
Caudate	–0.0016 (0.0054)	0.77			–2.3E – 03	0.67
Hippocampus	0.01 (0.0053)	0.053			0.01	0.04
SurfArea	–0.0095 (0.0056)	0.091	0.02	0.13	7.3E – 04	0.78
ICV	0.029 (0.0055)	2.4E – 07	–0.1	0.07	–0.03	2.4E – 03
Reasoning and problem solving						
Caudate	–0.0059 (0.0091)	0.51			5.7E – 03	0.55
Hippocampus	0.0031 (0.0089)	0.73			–9.6E – 05	0.95
SurfArea	0.052 (0.0094)	2.6E – 08	0.06	0.250	–7.4E – 04	0.97
ICV	0.15 (0.0092)	3.7E – 59	0.25	0.24	0.18	0.04
Symbol digit substitution						
Caudate	0.0011 (0.0077)	0.88			–4.2E – 03	0.83
Hippocampus	0.04 (0.0075)	6.5E – 08			–0.01	0.82
SurfArea	0.055 (0.0079)	3.8E – 12	0.05	2.4E – 03	6.9E – 04	0.99
ICV	0.066 (0.0079)	3.6E – 17	0.1	4.0E – 04	0.13	0.68
Trail making A						
Caudate	0.034 (0.0084)	5.7E – 05			4.4E – 04	1
Hippocampus	0.04 (0.0081)	1.0E – 06			3.0E – 03	0.97
SurfArea	0.046 (0.0086)	1.1E – 07	0.09	0.19	1.1E – 03	0.98
ICV	0.059 (0.0085)	6.1E – 12	0.21	0.20	–0.01	0.99
Trail making B						
Caudate	0.021 (0.0083)	0.012			–0.01	0.79
Hippocampus	0.04 (0.008)	6.9E – 07			–0.01	0.86
SurfArea	0.082 (0.0085)	6.4E – 22	0.07	8.0E – 04	8.9E – 03	0.92
ICV	0.11 (0.0084)	1.2E – 36	0.17	1.2E – 03	0.16	0.73

Path B is the effect of the brain structure on cognition overall including all 1q21.1 deletion and duplication carriers (4–13 CNV carriers in each group) and non-carriers ($n = 10,501$ – $30,924$; for exact numbers, see Supplementary Table 13). Each calculation included 5000 simulations. The significance value for multiple comparisons (1.4×10^{-3}) are in bold

assembly. This may explain the lack of GWAS hits in the region.

Candidates for a dosage-dependent amplifier of the CNV-associated brain phenotypes are the recently identified human-specific *NOTCH2NL* genes that confer

delayed neuronal differentiation and increased progenitor self-renewal^{22,23}—in line with the radial unit hypothesis⁵². The areas with the highest regional effect sizes overlap with the areas of the highest expression of *NOTCH2NLA* and *C* in utero²² in concordance with an early

developmental effect such as the macrocephaly observed in utero in a 1q21.1 distal duplication carrier³⁸. Our observations of a 2% reduced skull diameter in the 1q21.1 deletion mouse (Supplementary Fig. 7 and Supplementary Notes 8 and 9) and recent findings of decreased total brain volume focused on the temporo-parietal and sub-cortical areas in the deletion mouse⁶⁰ suggest that genes overlapping between human and mice (nine of ten mice genes are syntenic to the human region⁴²) and not specific to humans are also involved in the altered skull and brain morphology. However, although diameter and volume are not directly comparable, the 17% decrease in ICV in human 1q21.1 deletion carriers would still point towards a substantial role of human-specific genes or genes with altered functions in comparison to mice. This underlines the need for additional data to disentangle which specific genes are involved in the skull and brain structural phenotypes. Of note, we also observed shorter bones overall in the 1q21.1 deletion mice (Supplementary Fig. 8 and Supplementary Note 9), expanding on previous head-to-tail length data⁴², and lower bone mineral density in female mice (Supplementary Fig. 9 and Supplementary Note 9), which mirror bone characteristics from human deletion carriers³⁴ increasing the number of observed cross-species effects between the 1q21.1 mice and human 1q21.1 deletion carriers.

1q21.1 distal CNV deletion and duplication carriers show deficits in different cognitive functions

Our findings of widespread lower performance across several tests in different domains for both carrier groups in the volunteer-based UK Biobank sample are in line with cognitive results from a recent study³³ and support that cognitive function in CNV carriers largely without a neurodevelopmental diagnosis may still be compromised^{8,16}. Interestingly, the frontal and cingulate regions⁶¹, with the greatest cortical effect sizes for distal 1q21.1, correlate particularly with cognitive function and have gone through the greatest expansion during human development and evolution⁶². Our analyses indicated that the decreases in cognitive task performance are partially mediated by the observed differences in ICV and cortical surface area, reflecting the positive correlation between brain volume and intellectual function in line with previous findings⁶³. The decrease in performance for several cognitive tasks in duplication carriers despite a larger ICV and cortical surface area suggests that the positive correlations may only be applicable within a certain narrower range. Interestingly, recent genetic analysis of *NOTCH2NL* in archaic and modern humans revealed ongoing adaptive evolution towards a lower dosage of the protein⁶⁴, suggesting negative effects of excessive *NOTCH2NL* protein.

Our brain structural findings in 1q21.1 distal CNV carriers overlap with brain alterations in associated

disorders: for example, ADHD⁶⁵, autism spectrum disorders⁶⁶, schizophrenia⁶⁷, bipolar disorder⁶⁸, major depressive disorder⁶⁹ and subtypes of epilepsy⁷⁰, but the exact overlaps differ between carrier groups. Of note, 1q21.1 distal deletion and duplication carriers display direct, opposite effects on several brain structures, while at risk for the same neurodevelopmental diseases. Other pathogenic CNVs also display overlapping disease risk and similar opposite copy number effects^{6,8–15} including effects on the cortical surface area in 22q11 and 16p11.2 proximal CNV carriers^{6,12–14}. These CNVs impact different genes, but may converge on the same downstream pathways altering cortical surface area formation, similar to what has been reported for behavioural and neuro-cognitive phenotypes²⁸.

This also suggests that other risk factors interplay to cause disease. It also supports that subgroups within neurodevelopmental disorders can be defined based on genetic profile and brain structural differences.

We demonstrate large effects of 1q21.1 distal CNVs on brain structure and cognition in humans including a mediation effect. These findings provide insight into molecular mechanisms involved in critical stages of human brain development and mapping of gene dosages to brain structural fingerprints.

Acknowledgements

1000BRAINS: The 1000BRAINS study was funded by the Institute of Neuroscience and Medicine, Research Center Juelich, Germany. We thank the Heinz Nixdorf Foundation (Germany) for the generous support of the Heinz Nixdorf Recall Study on which 1000BRAINS is based. We also thank the scientists and the study staff of the Heinz Nixdorf Recall Study and 1000BRAINS. Funding was also granted by the Initiative and Networking Fund of the Helmholtz Association (Caspers) and the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement 945539 (Human Brain Project SGA3; Amunts, Caspers, Cichon).

Brainscale: The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Dorret I. Boomsma), 51.02.060 (Hilleke E. Hulshoff Pol), 668.772 (Dorret I. Boomsma and Hilleke E. Hulshoff Pol); NWO/SPI 56-464-14192 (Dorret I. Boomsma), the European Research Council (ERC-230374) (Dorret I. Boomsma), High Potential Grant Utrecht University (Hilleke E. Hulshoff Pol) and NWO Brain and Cognition 433-09-220 (Hilleke E. Hulshoff Pol).

Betula: The Betula study was funded by the Knut and Alice Wallenberg (KAW) foundation (Nyberg). The Freesurfer segmentations on the Betula sample were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) at HPC2N (in Umeå, Sweden), partially funded by the Swedish Research Council through grant agreement no. 2018-05973.

Brain Imaging Genetics (BIG): This work makes use of the BIG database, first established in Nijmegen, The Netherlands, in 2007. This resource is now part of Cognomics (www.cognomics.nl), a joint initiative by researchers from the Donders Centre for Cognitive Neuroimaging, the Human Genetics and Cognitive Neuroscience departments of the Radboud University Medical Centre and the Max Planck Institute for Psycholinguistics in Nijmegen. The Cognomics Initiative has received support from the participating departments and centres and from external grants, that is, the Biobanking and Biomolecular Resources Research Infrastructure (Netherlands) (BBMRI-NL), the Hersenstichting Nederland and the Netherlands Organization for Scientific Research (NWO). The research leading to these results also receives funding from the NWO Gravitation grant 'Language in Interaction', the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement nos. 602450 (IMAGEMEND), 278948 (TACTICS) and 602805 (Aggressotype), as well as from the European Community's Horizon 2020

programme under grant agreement no. 643051 (MiND) and from ERC-2010-AdG 268800-NEUROSCHEMA. In addition, the work was supported by a grant for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership.

deCODE genetics: deCODE genetics acknowledges support from the Innovative Medicines Initiative Joint Undertaking under grant agreement nos. 115008 (NEWMEDS) and 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007-2013), EU-FP7-funded grant agreement no. 602450 (IMAGEMEND) and EU-funded FP7-People-2011-IAPP grant agreement no. 286213 (PsychDPC).

Dublin: This work was supported by Science Foundation Ireland (SFI grant 12/IP/1359 to Gary Donohoe and grant SFI08/IN.1/B1916-Corvin to Aidan C. Corvin).

ECHO-DEFINE: The ECHO study acknowledges funding from a Medical Research Council (MRC) Centre Grant to Michael J. Owen (G0801418), the Wellcome Trust (Institutional Strategic Support Fund (ISSF) to van den Bree and Clinical Research Training Fellowship to Joanne L. Doherty), the Waterloo Foundation (WF 918-1234 to van den Bree), the Baily Thomas Charitable Fund (2315/1 to van den Bree), National Institute of Mental Health (NIMH 5U01MH101724 to van den Bree and Michael J. Owen), the IMAGINE-2 study (funded by the MRC (MR/T033045/1) to van den Bree, Jeremy Hall and Michael J. Owen), the IMAGINE-ID study (funded by MRC (MR/N022572/1) to Jeremy Hall, van den Bree and Owen). The DEFINE study was supported by a Wellcome Trust Strategic Award (100202/Z/12/Z) to Michael J. Owen.

ENIGMA: ENIGMA is supported in part by NIH grants U54 EB20403, R01MH116147 and R56AG058854. NIA T32AG058507; NIH/NIMH 5T32MH073526.

EPiGEN-Dublin: The EPiGEN-Dublin cohort was supported by a Science Foundation Ireland Research Frontiers Programme award (08/RFP/GEN1538).

EPiGEN-UK (Sisodiya): The work was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme. We are grateful to the Wolfson Trust and the Epilepsy Society for supporting the Epilepsy Society MRI scanner.

GAP: This work was supported by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience, King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

GOBS: The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111 and R01 MH083824, with work conducted in part in facilities constructed under the support of NIH grant C06 RR020547.

GSP: Data were in part provided by the Brain Genomics Superstruct Project (GSP) of Harvard University and Massachusetts General Hospital (MGH) (Principal Investigators: Randy Buckner, Jordan Smoller and Joshua Roffman), with support from the Center for Brain Science Neuroinformatics Research Group, Athinoula A. Martinos Center for Biomedical Imaging, Center for Genomic Medicine and Stanley Center for Psychiatric Research. Twenty individual investigators at Harvard and MGH generously contributed data to the overall project. We would like to thank Randy Buckner for insightful comments and feedback on this work.

HUBIN: The HUBIN study was financed by the Swedish Research Council (K2010-62X-15078-07-2, K2012-61X-15078-09-3, 521-2014-3487 K2015-62X-15077-12-3, 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet.

HUNT: The HUNT study is a collaboration between HUNT Research Centre (Faculty of Medicine and Movement Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI.

IMAGEN: This work received support from the following sources: the European Union-funded FP6 Integrated Project IMAGEN (reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network based stratification of reinforcement-related disorders) (695313), ERANID (Understanding the Interplay between Cultural, Biological and

Subjective Factors in Drug Use Pathways) (PR-ST-0416-10004), BRIDGET (JPND: BBrain Imaging, cognition Dementia and next generation GENomics) (MR/N027558/1), Human Brain Project (HBP SGA 2, 785907), the FP7 projects IMAGEMEND(602450; IMAGING GENetics for MENTAL Disorders) and MATRICS (603016), the Innovative Medicine Initiative Project EUAIMS (115300-2), the Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the Swedish Research Council FORMAS, the Medical Research Council, the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Bundesministerium für Bildung und Forschung (BMBF grants 01GS08152, 01EV0711; eMED SysAlc01ZX1311A; Forschungsnetz AERIAL 01EE1406A, 01EE1406B), the Deutsche Forschungsgemeinschaft (DFG grants, SM 80/7-2, SFB 940/2), the Medical Research Foundation and Medical Research Council (grants MR/R00465X/1 and MR/S020306/1). Further support was provided by grants from: ANR (project AF12-NEUR0008-01—WM2NA, ANR-12-SAMA-0004), the Eranet Neuron (ANR-18-NEUR00002-01), the Fondation de France (00081242), the Fondation pour la Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l'Avenir (grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes of Health, Science Foundation Ireland (16/ERC/D/3797), USA (Axon, Testosterone and Mental Health during Adolescence; R01 MH085772-01A1) and by NIH Consortium grant U54 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence.

Lifespan: The study is funded by the Research Council of Norway (230345, 288083 and 223273).

NCNG: NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the Research Council of Norway, to le Hellard, Steen and Espeseth. The Bergen group was supported by grants from the Western Norway Regional Health Authority (Grant 911593 to Arvid Lundervold, Grant 911397 and 911687 to Astrid Johansen Lundervold).

NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organisation for Health Research and Development (ZonMW) grants 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004,463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity programme—024.001.003, NWO-Groot 480-15-001/674, Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK (2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL, 184.021.007 and 184.033.111); Spinozapremie (NWO-56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (URF) to Dorret I. Boomsma; Amsterdam Public Health research institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community's Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council (ERC Starting 284167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the National Institutes of Health (NIH, R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01 DK092127-04, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by NWO through grant 2018/EW/00408559, BIG Grid, the Dutch e-Science Grid and SURFSARA.

OATS: The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Programme (ID No. 401162) and NHMRC Project Grants (ID Nos. 1045325 and 1085606). This research was facilitated through Twins Research Australia, a national resource in part supported by an NHMRC Centre for Research Excellence Grant (ID No.: 1079102). We thank the participants for their time and generosity in contributing to this research. We acknowledge the contribution of the OATS research team (<https://cheba.unsw.edu.au/project/older-australian-twins-study>) to this study. OATS genotyping was partly funded by a Commonwealth Scientific and Industrial Research Organization Flagship Collaboration Fund Grant.

Osaka: Osaka study was supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS: Grant Number JP18dm0207006), Brain/MINDS& beyond studies (Grant Number JP20dm0307002) and Health and Labour Sciences Research Grants for Comprehensive Research on Persons with Disabilities (Grant Number JP20dk0307081) from the Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research (KAKENHI; Grant Numbers JP25293250 and JP16H05375). Some computations were performed at the Research Center for Computational Science, Okazaki, Japan.

PAFIP: The PAFIP study was supported by Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant CI2005-0308007 and the FundaciónMarqués de Valdecilla API07/011. Biological samples from our cohort were stored at the Valdecilla Biobank and genotyping services were conducted at the Spanish 'Centro Nacional de Genotipado' (CEGEN-HSCII).

MIC/COBRE: The study is funded by the National Institutes of Health studies R01EB006841, P20GM103472 and P30GM122734 and Department of Energy DE-FG02-99ER62764.

PING: Data collection and sharing for the Paediatric Imaging, Neurocognition and Genetics (PING) Study (National Institutes of Health Grant RC2DA029475) were funded by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health & Human Development. A full list of PING investigators is at <http://pingstudy.ucsd.edu/investigators.html>.

QTIM: The QTIM study was supported by the National Institute of Child Health and Human Development (R01 HD050735) and the National Health and Medical Research Council (NHMRC 486682, 1009064), Australia. Genotyping was supported by NHMRC (389875). Medland is supported in part by an NHMRC fellowship (APP1103623).

SHIP: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grant nos. 01ZZ9603, 01ZZ0103 and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide single-nucleotide polymorphism typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania.

StrokeMRI: StrokeMRI was supported by the Norwegian ExtraFoundation for Health and Rehabilitation(2015/FO5146), the Research Council of Norway (249795, 262372), the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073) and the Department of Psychology, University of Oslo.

Sydney MAS: The Sydney Memory and Aging Study (Sydney MAS) is funded by National and HealthMedical Research Council (NHMRC) Programme and Project Grants (ID350833, ID568969 and ID109308). We also thank the Sydney MAS participants and the Research Team.

SYS: The SYS Study is supported by Canadian Institutes of Health Research.

TOP: Centre of Excellence: (RCN #23273 and RCN #226971). Part of this work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) (tsd-drift@usit.uio.no). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7-PEOPLE-2013-COFUND) under grant agreement no. 609020—Scientia Fellows; the Research Council of Norway (RCN) #276082—A lifespan perspective on mental illness: toward precision medicine using multimodal brain imaging and genetics. Ida E. Sønderby and Rune Bøen are supported by South-Eastern Norway Regional Health Authority (#2020060). Ida E. Sønderby and Ole A. Andreassen have received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant agreement no. 847776 (CoMorMent project) and the KG Jebsen Foundation (SKGJ-MED-021).

UCLA_UMCU: The UCLA_UMCU cohort comprises of six studies which were supported by National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) (20244 to Prof. Hillegers), The Netherlands Organisation for Health Research and Development (ZonMw) (908-02-123 to Prof. Hulshoff Pol), and Netherlands Organisation for Scientific Research (NWO 9120818 and NWO-VIDI 917-46-370 to Prof. Hulshoff Pol). The GROUP study was funded through the Geestkracht programme of the Dutch Health Research Council (ZonMw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly and Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health

institutions: GGZ inGeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord-Holland-Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia Psycho-medical Center, The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh, voor Geestelijke Gezondheid, Mondriaan, Vireneriagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-JozefKortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Elizabeth Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht, GGZ Centraal and Delta).

UK Biobank: This work made use of data sharing from UK Biobank (under project code 27412).

Others: Work by Pierre Vanderhaeghen was funded by Grants of the European Research Council (ERC Adv Grant GENDEVOCORTEX), the EOS Programme, the Belgian FWO, the AXA Research Fund and the Belgian Queen Elizabeth Foundation. Ikuo K. Suzuki was supported by a postdoctoral fellowship of the FRS/FNRS.

Data availability

The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary information files. The data were gathered from various resources, and material requests will need to be placed with individual PIs. I.E.S. can provide additional detail upon correspondence. Data from PING are available at NIMH Data Archive: https://ndar.nih.gov/edit_collection.html?id=2607

Conflict of interest

H.B. is an advisory board member for Nutricia Australia. He has received research funding from the EU 'Joint Programme Neurodegenerative Disorders' (JPND) and the National Health and Medical Research Council, Australia. H.J.G. has received travel grants and speakers honoraria from Fresenius Medical Care, Servier, Neuraxpharm and Janssen Cilag. He has received research funding from the German Research Foundation (DFG), the German Ministry of Education and Research (BMBF), the DAMP Foundation, Fresenius Medical Care, the EU 'Joint Programme Neurodegenerative Disorders' (JPND) and the European Social Fund (ESF). C.R.K.C., P.M.T. and N.J. received partial grant support from Biogen Inc. (Boston), for research unrelated to the topic of this manuscript. B.C.-F. has received honoraria from Janssen Cilag, Otsuka and Lundbeck for educational and advisory/consultant activities unrelated with the present research. A.M.D. is a Founder of and holds equity in CorTechs Labs Inc., and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity Inc., and receives funding through a research agreement with General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. G.B.W., O.G., M.O.U., H.S. and K.S. are employees of deCODE genetics (Amgen). D.P.H. is an employee of Genentech Inc. O.A.A. has received speakers honorarium from Lundbeck, and is a consultant to HealthLytx. A.J.L. has received speaker's honorarium from Shire. M.J.O., J.H. and v.d.B. report grants from Takeda Pharmaceuticals outside of the submitted work. D.J.S. has received research grants and/or consultancy honoraria from Lundbeck and Sun. D.E.J.L. receives book royalties from Springer Nature and Oxford University Press. T.F. is on the Novo Nordisk advisory board. P.S.S. is on the Expert Advisory Committee of Biogen Australia. All other authors declare no competing financial interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41398-021-01213-0>.

Received: 26 November 2020 Revised: 23 December 2020 Accepted: 8 January 2021
Published online: 22 March 2021









References

- Toga, A. W. & Thompson, P. M. Genetics of brain structure and intelligence. *Annu. Rev. Neurosci.* **28**, 1–23 (2005).
- Hibar, D. P. et al. Novel genetic loci associated with hippocampal volume. *Nat. Commun.* **8**, 13624 (2017).
- Hibar, D. P. et al. Common genetic variants influence human subcortical brain structures. *Nature* **520**, 224–229 (2015).
- Meda, S. A., Pryweller, J. R. & Thornton-Wells, T. A. Regional brain differences in cortical thickness, surface area and subcortical volume in individuals with Williams syndrome. *PLoS ONE* **7**, e31913 (2012).
- Fan, C. C. et al. Williams syndrome-specific neuroanatomical profile and its associations with behavioral features. *Neuroimage Clin.* **15**, 343–347 (2017).
- Lin, A. et al. Mapping 22q11.2 gene dosage effects on brain morphometry. *J. Neurosci.* **37**, 6183–6199 (2017).
- Sun, D. et al. Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: convergence with idiopathic psychosis and effects of deletion size. *Mol. Psychiatry* **25**, 1822–1834 (2020).
- Stefansson, H. et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature* **505**, 361–366 (2014).
- Silva, A. I. et al. Reciprocal white matter changes associated with copy number variation at 15q11.2 BP1-BP2: a diffusion tensor imaging study. *Biol. Psychiatry* **85**, 563–572 (2019).
- Ulfarsson, M. O. et al. 15q11.2 CNV affects cognitive, structural and functional correlates of dyslexia and dyscalculia. *Transl. Psychiatry* **7**, e1109 (2017).
- van der Meer, D. et al. Association of copy number variation of the 15q11.2 BP1-BP2 region with cortical and subcortical morphology and cognition. *JAMA Psychiatry* **77**, 420–430 (2019).
- Maillard, A. M. et al. The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. *Mol. Psychiatry* **20**, 140–147 (2015).
- Qureshi, A. Y. et al. Opposing brain differences in 16p11.2 deletion and duplication carriers. *J. Neurosci.* **34**, 11199–11211 (2014).
- Martin-Brevet, S. et al. Quantifying the effects of 16p11.2 copy number variants on brain structure: a multi-site genetic-first study. *Biol. Psychiatry* **84**, 253–264 (2018).
- Sønderby, I. E. et al. Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. *Mol. Psychiatry* **25**, 584–602 (2018).
- Kendall, K. M. et al. Cognitive performance among carriers of pathogenic copy number variants: analysis of 152,000 UK Biobank subjects. *Biol. Psychiatry* **82**, 103–110 (2016).
- Huguet, G. et al. Measuring and estimating the effect sizes of copy number variants on general intelligence in community-based samples. *JAMA Psychiatry* **75**, 447–457 (2018).
- Hippolyte, L. et al. The number of genomic copies at the 16p11.2 locus modulates language, verbal memory, and inhibition. *Biol. Psychiatry* **80**, 129–139 (2016).
- Bernier, R. et al. Clinical phenotype of the recurrent 1q21.1 copy-number variant. *Genet. Med.* **18**, 341–349 (2016).
- Brunetti-Piéri, N. et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. *Nat. Genet.* **40**, 1466–1471 (2008).
- Rosenfeld, J. A. et al. Proximal microdeletions and microduplications of 1q21.1 contribute to variable abnormal phenotypes. *Eur. J. Hum. Genet.* **20**, 754–761 (2012).
- Suzuki, I. K. et al. Human-specific NOTCH2NL genes expand cortical neurogenesis through Delta/Notch regulation. *Cell* **173**, 1370–1384.e1316 (2018).
- Fiddes, I. T. et al. Human-specific NOTCH2NL genes affect notch signaling and cortical neurogenesis. *Cell* **173**, 1356–1369.e1322 (2018).
- PGC PCaSWGot. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat. Genet.* **49**, 27–35 (2017).
- Stefansson, H. et al. Large recurrent microdeletions associated with schizophrenia. *Nature* **455**, 232–236 (2008).
- Haldeman-Englert, C. R. & Jewett, T. in *GeneReviews((R))* (eds Adam, M. P. et al.) (University of Washington, Seattle University of Washington, 1993).
- Mefford, H. C. et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. *N. Engl. J. Med.* **359**, 1685–1699 (2008).
- Chawner, S. et al. Genotype-phenotype associations in children with copy number variants associated with high neuropsychiatric risk in the UK (IMAGINE-ID): a case-control cohort study. *Lancet Psychiatry* **6**, 493–505 (2019).
- Gourari, I., Schubert, R. & Prasad, A. 1q21.1 Duplication syndrome and epilepsy: case report and review. *Neurol. Genet.* **4**, e219 (2018).
- Gudmundsson, O. O. et al. Attention-deficit hyperactivity disorder shares copy number variant risk with schizophrenia and autism spectrum disorder. *Transl. Psychiatry* **9**, 258 (2019).
- Green, E. K. et al. Copy number variation in bipolar disorder. *Mol. Psychiatry* **21**, 89–93 (2016).
- Kendall, K. M. et al. Association of rare copy number variants with risk of depression. *JAMA Psychiatry* **76**, 818–825 (2019).
- Kendall, K. M. et al. Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank. *Br. J. Psychiatry* **214**, 297–304 (2019).
- Owen, D. et al. Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. *BMC Genomics* **19**, 867 (2018).
- Mace, A. et al. CNV-association meta-analysis in 191,161 European adults reveals new loci associated with anthropometric traits. *Nat. Commun.* **8**, 744 (2017).
- Crawford, K. et al. Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank. *J. Med. Genet.* **56**, 131–138 (2018).
- Dolcetti, A. et al. 1q21.1 Microduplication expression in adults. *Genet. Med.* **15**, 282–289 (2013).
- Verhagen, J. M. et al. Phenotypic variability associated with a large recurrent 1q21.1 microduplication in a three-generation family. *Mol. Syndromol.* **6**, 71–76 (2015).
- Soemedi, R. et al. Phenotype-specific effect of chromosome 1q21.1 rearrangements and GJA5 duplications in 2436 congenital heart disease patients and 6760 controls. *Hum. Mol. Genet.* **21**, 1513–1520 (2012).
- Buse, M. et al. Expanding the phenotype of reciprocal 1q21.1 deletions and duplications: a case series. *Ital. J. Pediatr.* **43**, 61 (2017).
- Rosenfeld, J. A., Coe, B. P., Eichler, E. E., Cuckle, H. & Shaffer, L. G. Estimates of penetrance for recurrent pathogenic copy-number variations. *Genet. Med.* **15**, 478–481 (2013).
- Nielsen, J. et al. A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission. *Transl. Psychiatry* **7**, 1261 (2017).
- Sharp, A. J. et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. *Nat. Genet.* **38**, 1038–1042 (2006).
- O'Bleness, M. et al. Finished sequence and assembly of the DUF1220-rich 1q21 region using a haploid human genome. *BMC Genomics* **15**, 387 (2014).
- Dumas, L. J. et al. DUF1220-domain copy number implicated in human brain-size pathology and evolution. *Am. J. Hum. Genet.* **91**, 444–454 (2012).
- Florio, M. et al. Evolution and cell-type specificity of human-specific genes preferentially expressed in progenitors of fetal neocortex. *eLife* **7**, e32332 (2018).
- Fiddes, I. T., Pollen, A. A., Davis, J. M. & Sikela, J. M. Paired involvement of human-specific Olduvai domains and NOTCH2NL genes in human brain evolution. *Hum. Genet.* **138**, 715–721 (2019).
- Harvard, C. et al. Understanding the impact of 1q21.1 copy number variant. *Orphanet J. Rare Dis.* **6**, 54 (2011).
- Miller, K. L. et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat. Neurosci.* **19**, 1523–1536 (2016).
- Wang, K. et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* **17**, 1665–1674 (2007).
- Wickham, H. *ggplot2: Elegant Graphics for Data Analysis* (Springer, 2009).
- Rakic, P. A small step for the cell, a giant leap for mankind: a hypothesis of neocortical expansion during evolution. *Trends Neurosci.* **18**, 383–388 (1995).
- Grasby, K. L. et al. The genetic architecture of the human cerebral cortex. *Science* **367**, eaay6690, <https://doi.org/10.1126/science.aay6690> (2020).
- Di Donato, N. et al. Lissencephaly: expanded imaging and clinical classification. *Am. J. Med. Genet. A* **173**, 1473–1488 (2017).
- Libby, J. et al. Modelling human skull growth: a validated computational model. *J. R. Soc. Interface* **14**, 20170202, <https://doi.org/10.1098/rsif.2017.0202> (2017).
- Warland, A., Kendall, K. M., Rees, E., Kirov, G. & Caseras, X. Schizophrenia-associated genomic copy number variants and subcortical brain volumes in the UK Biobank. *Mol. Psychiatry* **25**, 854–862 (2019).
- Adams, H. H. et al. Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nat. Neurosci.* **19**, 1569–1582 (2016).

58. Hofer, E. et al. Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. *Nat. Commun.* **11**, 4796 (2020).
59. Steinberg, K. M. et al. Single haplotype assembly of the human genome from a hydatidiform mole. *Genome Res.* **24**, 2066–2076 (2014).
60. Reinwald, J. R. et al. Separable neural mechanisms for the pleiotropic association of copy number variants with neuropsychiatric traits. *Transl. Psychiatry* **10**, 93 (2020).
61. Hill, J. et al. Similar patterns of cortical expansion during human development and evolution. *Proc. Natl Acad. Sci. USA* **107**, 13135 (2010).
62. Fjell, A. M. et al. High-expanding cortical regions in human development and evolution are related to higher intellectual abilities. *Cereb. Cortex* **25**, 26–34 (2015).
63. Deary, I. J., Penke, L. & Johnson, W. The neuroscience of human intelligence differences. *Nat. Rev. Neurosci.* **11**, 201–211 (2010).
64. Lodewijk, G. A., Fernandes, D. P., Vretzakis, I., Savage, J. E. & Jacobs, F. M. J. Evolution of human brain-size associated NOTCH2NL genes proceeds towards reduced protein levels. *Mol. Biol. Evol.* **37**, 2531–2548 (2020).
65. Hoogman, M. et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. *Lancet Psychiatry* **4**, 310–319 (2017).
66. van Rooij, D. et al. Cortical and subcortical brain morphometry differences between patients with autism spectrum disorder and healthy individuals across the lifespan: results from the ENIGMA ASD Working Group. *Am. J. Psychiatry* **175**, 359–369 (2018).
67. van Erp, T. G. et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol. Psychiatry* **21**, 547–553 (2016).
68. Hibar, D. P. et al. Subcortical volumetric abnormalities in bipolar disorder. *Mol. Psychiatry* **21**, 1710–1716 (2016).
69. Schmaal, L. et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. *Mol. Psychiatry* **21**, 806–812 (2016).
70. Whelan, C. D. et al. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. *Brain* **141**, 391–408 (2018).

Author details

Ida E. Sønderby^{1,2,3}, Dennis van der Meer^{1,4}, Clara Moreau^{5,6}, Tobias Kaufmann^{1,7}, G. Bragi Walters^{8,9}, Maria Ellegaard¹⁰, Abdel Abdellaoui^{11,12}, David Ames^{13,14}, Katrin Amunts^{15,16}, Micael Andersson^{17,18}, Nicola J. Armstrong¹⁹, Manon Bernard²⁰, Nicholas B. Blackburn²¹, John Blangero²¹, Dorret I. Boomsma^{12,22,23}, Henry Brodaty^{24,25}, Rachel M. Brouwer²⁶, Robin Bülow²⁷, Rune Bøen^{1,2}, Wiepke Cahn^{26,28}, Vince D. Calhoun^{29,30}, Svenja Caspers^{15,31}, Christopher R. K. Ching³², Sven Cichon^{15,33,34}, Simone Ciufolini³⁵, Benedicto Crespo-Facorro^{36,37}, Joanne E. Curran²¹, Anders M. Dale³⁸, Shareefa Dalvie³⁹, Paola Dazzan⁴⁰, Eco J. C. de Geus^{12,22,23}, Greig I. de Zubicaray⁴¹, Sonja M. C. de Zwarte²⁶, Sylvane Desrivieres⁴², Joanne L. Doherty^{43,44}, Gary Donohoe⁴⁵, Bogdan Draganski^{46,47}, Stefan Ehrlich⁴⁸, Else Eising⁴⁹, Thomas Espeseth^{50,51}, Kim Fejgin⁵², Simon E. Fisher^{49,53}, Tormod Fladby^{54,55}, Oleksandr Frei¹, Vincent Frouin⁵⁶, Masaki Fukunaga^{57,58}, Thomas Gareau⁵⁶, Tian Ge^{59,60,61}, David C. Glahn^{62,63,64}, Hans J. Grabe^{65,66}, Nynke A. Groenewold³⁹, Ómar Gústafsson⁸, Jan Haavik^{67,68}, Asta K. Haberg^{69,70}, Jeremy Hall^{43,71}, Ryota Hashimoto^{72,73}, Jayne Y. Hehir-Kwa⁷⁴, Derrek P. Hibar⁷⁵, Manon H. J. Hillegers⁷⁶, Per Hoffmann^{34,77}, Laurena Holleran⁴⁵, Avram J. Holmes^{78,79,80}, Georg Homuth⁸¹, Jouke-Jan Hottenga^{12,22,23}, Hilleke E. Hulshoff Pol²⁶, Masashi Ikeda⁸², Neda Jahanshad³², Christiane Jockwitz^{15,31}, Stefan Johansson^{83,84}, Erik G. Jönsson^{85,86}, Niklas R. Jørgensen^{87,88}, Masataka Kikuchi⁸⁹, Emma E. M. Knowles^{62,64}, Kuldeep Kumar⁵, Stephanie Le Hellard^{90,91}, Costin Leu^{61,92,93,94}, David E. J. Linden^{44,3}, Jingyu Liu²⁹, Arvid Lundervold^{67,95}, Astri Johansen Lundervold⁹⁶, Anne M. Maillard⁹⁷, Nicholas G. Martin⁹⁸, Sandra Martin-Brevet⁴⁶, Karen A. Mather^{24,99}, Samuel R. Mathias^{62,64}, Katie L. McMahon¹⁰⁰, Allan F. McRae^{101,102}, Sarah E. Medland¹⁰³, Andreas Meyer-Lindenberg¹⁰⁴, Torgeir Moberget^{1,50}, Claudia Modenato^{46,105}, Jennifer Monereo Sánchez^{106,107}, Derek W. Morris⁴⁵, Thomas W. Mühleisen^{15,16,33}, Robin M. Murray¹⁰⁸, Jacob Nielsen⁵², Jan E. Nordvik¹⁰⁹, Lars Nyberg^{17,18,110}, Loes M. Olde Loohuis¹¹¹, Roel A. Ophoff^{111,112}, Michael J. Owen⁴³, Tomas Paus^{113,114}, Zdenka Pausova^{20,114}, Juan M. Peralta²¹, G. Bruce Pike¹¹⁵, Carlos Prieto¹¹⁶, Erin B. Quinlan¹¹⁷, Céline S. Reinbold^{33,34,50}, Tiago Reis Marques^{118,119}, James J. H. Rucker¹²⁰, Perminder S. Sachdev^{24,121}, Sigrid B. Sando^{69,122}, Peter R. Schofield^{123,124}, Andrew J. Schork^{125,126}, Gunter Schumann¹¹⁷, Jean Shin^{20,114}, Elena Shumskaya^{53,127}, Ana I. Silva^{44,3,44}, Sanjay M. Sisodiya^{92,94}, Vidar M. Steen^{90,91}, Dan J. Stein¹²⁸, Lachlan T. Strike¹⁰², Ikuo K. Suzuki^{129,130,131}, Christian K. Tamnes^{1,132,133}, Alexander Teumer¹³⁴, Anbupalam Thalamuthu²⁴, Diana Tordesillas-Gutiérrez^{36,135}, Anne Uhlmann³⁹, Magnus O. Ulfarsson^{8,136}, Dennis van 't Ent^{12,22}, Marianne B. M. van den Bree^{43,71}, Pierre Vanderhaeghen^{137,138,139}, Evangelos Vassos^{108,140}, Wei Wen²⁴, Katharina Wittfeld^{65,66},












Margaret J. Wright ^{102,141}, Ingrid Agartz ^{85,86,133}, Srdjan Djurovic ^{2,90}, Lars T. Westlye ^{1,3,50}, Hreinn Stefansson ⁸, Kari Stefansson ^{8,9}, Sébastien Jacquemont ^{5,142}, Paul M. Thompson ³², Ole A. Andreassen ¹ and for the ENIGMA-CNV working group

¹NORMENT, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ²Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. ³KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway. ⁴School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands. ⁵Sainte Justine Hospital Research Center, Montreal, Quebec, Canada. ⁶Centre de recherche de l'Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada. ⁷Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany. ⁸deCODE Genetics (Amgen), Reykjavik, Iceland. ⁹Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ¹⁰Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark. ¹¹Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. ¹²Department of Biological Psychology and Netherlands Twin Register, VU University Amsterdam, Amsterdam, the Netherlands. ¹³University of Melbourne Academic Unit for Psychiatry of Old Age, Kew, Australia. ¹⁴National Ageing Research Institute, Parkville, Australia. ¹⁵Institute of Neuroscience and Medicine, INM-1, Research Centre Jülich, Jülich, Germany. ¹⁶C. and O. Vogt Institute for Brain Research, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ¹⁷Umeå Centre for Functional Brain Imaging, Umeå University, Umeå, Sweden. ¹⁸Department of Integrative Medical Biology, Umeå University, Umeå, Sweden. ¹⁹Mathematics and Statistics, Murdoch University, Perth, Australia. ²⁰Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada. ²¹South Texas Diabetes and Obesity Institute, Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, USA. ²²Amsterdam Neuroscience, Amsterdam, the Netherlands. ²³Amsterdam Public Health Research Institute, VU Medical Center, Amsterdam, the Netherlands. ²⁴Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, Australia. ²⁵Dementia Centre for Research Collaboration, School of Psychiatry, University of New South Wales, Sydney, Australia. ²⁶Department of Psychiatry, University Medical Center Brain Center, Utrecht University, Utrecht, the Netherlands. ²⁷Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. ²⁸Altrecht Science, Utrecht, the Netherlands. ²⁹Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, USA. ³⁰The Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, USA. ³¹Institute for Anatomy I, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ³²Imaging Genetics Center, Mark and Mary Stevens Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, USA. ³³Department of Biomedicine, University of Basel, Basel, Switzerland. ³⁴Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. ³⁵Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. ³⁶University Hospital Marqués de Valdecilla, IDIVAL, Centro de Investigación Biomédica en Red Salud Mental (CIBERSAM), Santander, Spain. ³⁷University Hospital Virgen del Rocío, IBIS, Centre de Investigación Biomédica en Red Salud Mental (CIBERSAM), Sevilla, Spain. ³⁸Center for Multimodal Imaging and Genetics, University of California, San Diego, USA. ³⁹Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, Western Cape, South Africa. ⁴⁰Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. ⁴¹Faculty of Health, Queensland University of Technology, Brisbane, Australia. ⁴²Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. ⁴³MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom. ⁴⁴Cardiff University Brain Research Imaging Centre School of Psychology, Cardiff University, Cardiff, United Kingdom. ⁴⁵Centre for Neuroimaging and Cognitive Genomics, School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Galway, Ireland. ⁴⁶Laboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. ⁴⁷Neurology Department, Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany. ⁴⁸Division of Psychological and Social Medicine, Faculty of Medicine, TU Dresden, Dresden, Germany. ⁴⁹Language and Genetics Department, Max Planck Institute for Psycholinguistics, Nijmegen, the Netherlands. ⁵⁰Department of Psychology, University of Oslo, Oslo, Norway. ⁵¹Björknes College, Oslo, Norway. ⁵²Signal Transduction, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby, Denmark. ⁵³Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands. ⁵⁴Department of Neurology, Akershus University Hospital, 1474 Nordbyhagen, Norway. ⁵⁵Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway. ⁵⁶Université Paris-Saclay, CEA, Neurospin, 91191 Gif-sur-Yvette, France. ⁵⁷Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan. ⁵⁸Department of Life Science, Sokendai, Hayama, Japan. ⁵⁹Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ⁶⁰Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ⁶¹Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁶²Boston Children's Hospital, Boston, Massachusetts, USA. ⁶³Institute of Living, Hartford, Connecticut, USA. ⁶⁴Harvard Medical School, Boston, Massachusetts, USA. ⁶⁵Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany. ⁶⁶German Center of Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany. ⁶⁷Department of Biomedicine, University of Bergen, Bergen, Norway. ⁶⁸Division of Psychiatry, Haukeland University Hospital, Bergen, Norway. ⁶⁹Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway. ⁷⁰St Olav's Hospital, Department of Radiology and Nuclear Medicine, Trondheim, Norway. ⁷¹School of Medicine, Cardiff University, Cardiff, United Kingdom. ⁷²Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan. ⁷³Osaka University, Osaka, Japan. ⁷⁴Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. ⁷⁵Genentech, Inc., South San Francisco 94080 CA, USA. ⁷⁶Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC-Sophia, Rotterdam, the Netherlands. ⁷⁷Institute of Human Genetics, University of Bonn Medical School, Bonn, Germany. ⁷⁸Psychology Department, Yale University, New Haven, CT, USA. ⁷⁹Department of Psychiatry, Yale University, New Haven, CT, USA. ⁸⁰Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ⁸¹Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. ⁸²Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan. ⁸³Department of Clinical Science, University of Bergen, Bergen, Norway. ⁸⁴Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. ⁸⁵Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden. ⁸⁶Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ⁸⁷Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark. ⁸⁸Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁸⁹Department of Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan. ⁹⁰Norwegian Centre for Mental Disorders Research, Department of Clinical Science, University of Bergen, Bergen, Norway. ⁹¹Dr Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. ⁹²Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK. ⁹³Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States. ⁹⁴Chalfont Centre for Epilepsy, Chalfont-St-Peter, United Kingdom. ⁹⁵Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway. ⁹⁶Department of Biological and Medical Psychology, University of Bergen, Bergen, Norway. ⁹⁷Service des Troubles du Spectre de l'Autisme et apparentés, Lausanne University Hospital, Lausanne, Switzerland. ⁹⁸Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, Australia. ⁹⁹Neuroscience Research Australia, Randwick, Australia. ¹⁰⁰Herston Imaging Research Facility and School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia. ¹⁰¹Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia. ¹⁰²Queensland Brain Institute, University of Queensland, Brisbane, Australia. ¹⁰³Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. ¹⁰⁴Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ¹⁰⁵University of Lausanne, Lausanne, Switzerland. ¹⁰⁶Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands. ¹⁰⁷School for Mental Health and Neuroscience, Maastricht University,

Maastricht, the Netherlands. ¹⁰⁸Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. ¹⁰⁹The CatoSenteret Rehabilitation Center, Son, Norway. ¹¹⁰Department of Radiation Sciences, Umeå University, Umeå, Sweden. ¹¹¹Center for Neurobehavioral Genetics, University of California, Los Angeles, USA. ¹¹²Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. ¹¹³Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. ¹¹⁴Physiology and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. ¹¹⁵Departments of Radiology and Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. ¹¹⁶Bioinformatics Service, Nucleus, University of Salamanca, Salamanca, Spain. ¹¹⁷Centre for Population Neuroscience and Precision Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. ¹¹⁸Department of Psychosis, Institute of Psychiatry, Psychology & Neuroscience, Kings College, London, United Kingdom. ¹¹⁹Psychiatric Imaging Group, MRC London Institute of Medical Sciences (LMS), Hammersmith Hospital, Imperial College, London, United Kingdom. ¹²⁰Institute of Psychiatry, Psychology and Neuroscience, London, London, United Kingdom. ¹²¹Neuropsychiatric Institute, The Prince of Wales Hospital, Sydney, Australia. ¹²²University Hospital of Trondheim, Department of Neurology and Clinical Neurophysiology, Trondheim, Norway. ¹²³Neuroscience Research Australia, Sydney, Australia. ¹²⁴School of Medical Sciences, University of New South Wales, Sydney, Australia. ¹²⁵Institute of Biological Psychiatry, Roskilde, Denmark. ¹²⁶The Translational Genetics Institute (TGEN), Phoenix, AZ, United States. ¹²⁷Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. ¹²⁸South African Medical Research Council Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa. ¹²⁹VIB Center for Brain & Disease Research, Stem Cell and Developmental Neurobiology Lab, Leuven, Belgium. ¹³⁰University of Brussels (ULB), Institute of Interdisciplinary Research (IRIBHM) ULB Neuroscience Institute, Brussels, Belgium. ¹³¹The University of Tokyo, Department of Biological Sciences, Graduate School of Science, Tokyo, Japan. ¹³²PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway. ¹³³Department of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway. ¹³⁴Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. ¹³⁵Department of Radiology, Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute IDIVAL, Santander, Spain. ¹³⁶Faculty of Electrical and Computer Engineering, University of Iceland, Reykjavik, Iceland. ¹³⁷VIB-KU Leuven Center for Brain & Disease Research, 3000 Leuven, Belgium. ¹³⁸KU Leuven, Department of Neurosciences & Leuven Brain Institute, 3000 Leuven, Belgium. ¹³⁹Université Libre de Bruxelles (U.L.B.), Institut de Recherches en Biologie Humaine et Moléculaire (IRIBHM), and ULB Neuroscience Institute (UNI), 1070 Brussels, Belgium. ¹⁴⁰National Institute for Health Research, Mental Health Biomedical Research Centre, South London and Maudsley National Health Service Foundation Trust and King's College London, London, United Kingdom. ¹⁴¹Centre for Advanced Imaging, University of Queensland, Brisbane, Australia. ¹⁴²Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada

for the ENIGMA-CNV working group

Ida E. Sønderby ^{1,2,3}, Dennis van der Meer^{1,4}, Clara Moreau ^{5,6}, Tobias Kaufmann ^{1,7}, G. Bragi Walters ^{8,9}, Maria Ellegaard¹⁰, Abdel Abdellaoui ^{11,12}, David Ames^{13,14}, Katrin Amunts ^{15,16}, Micael Andersson^{17,18}, Nicola J. Armstrong ¹⁹, Manon Bernard²⁰, Nicholas B. Blackburn ²¹, John Blangero ²¹, Dorret I. Boomsma ^{12,22,23}, Henry Brodaty ^{24,25}, Rachel M. Brouwer²⁶, Robin Bülow ²⁷, Rune Bøen^{1,2}, Wiepke Cahn ^{26,28}, Vince D. Calhoun^{29,30}, Svenja Caspers^{15,31}, Christopher R. K. Ching³², Sven Cichon ^{15,33,34}, Simone Ciufolini³⁵, Benedicto Crespo-Facorro^{36,37}, Joanne E. Curran²¹, Anders M. Dale³⁸, Shareefa Dalvie ³⁹, Paola Dazzan ⁴⁰, Eco J. C. de Geus^{12,22,23}, Greig I. de Zubicaray⁴¹, Sonja M. C. de Zwarte²⁶, Sylvane Desrivieres ⁴², Joanne L. Doherty^{43,44}, Gary Donohoe⁴⁵, Bogdan Draganski ^{46,47}, Stefan Ehrlich⁴⁸, Else Eising ⁴⁹, Thomas Espeseth^{50,51}, Kim Fejgin⁵², Simon E. Fisher ^{49,53}, Tormod Fladby^{54,55}, Oleksandr Frei¹, Vincent Frouin ⁵⁶, Masaki Fukunaga^{57,58}, Thomas Gareau⁵⁶, Tian Ge^{59,60,61}, David C. Glahn^{62,63,64}, Hans J. Grabe ^{65,66}, Nynke A. Groenewold³⁹, Ómar Gústafsson⁸, Jan Haavik ^{67,68}, Asta K. Haberg^{69,70}, Jeremy Hall ^{43,71}, Ryota Hashimoto^{72,73}, Jayne Y. Hehir-Kwa⁷⁴, Derrek P. Hibar⁷⁵, Manon H. J. Hillegers ⁷⁶, Per Hoffmann ^{34,77}, Laurena Holleran⁴⁵, Avram J. Holmes ^{78,79,80}, Georg Homuth⁸¹, Jouke-Jan Hottenga ^{12,22,23}, Hilleke E. Hulshoff Pol²⁶, Masashi Ikeda ⁸², Neda Jahanshad ³², Christiane Jockwitz^{15,31}, Stefan Johansson ^{83,84}, Erik G. Jönsson^{85,86}, Niklas R. Jørgensen^{87,88}, Masataka Kikuchi ⁸⁹, Emma E. M. Knowles^{62,64}, Kuldeep Kumar ⁵, Stephanie Le Hellard^{90,91}, Costin Leu^{61,92,93,94}, David E. J. Linden^{4,43}, Jingyu Liu ²⁹, Arvid Lundervold^{67,95}, Astri Johansen Lundervold ⁹⁶, Anne M. Maillard ⁹⁷, Nicholas G. Martin⁹⁸, Sandra Martin-Brevet⁴⁶, Karen A. Mather ^{24,99}, Samuel R. Mathias^{62,64}, Katie L. McMahon ¹⁰⁰, Allan F. McRae ^{101,102}, Sarah E. Medland ¹⁰³, Andreas Meyer-Lindenberg¹⁰⁴, Torgeir Moberget^{1,50}, Claudia Modenato ^{46,105}, Jennifer Monereo Sánchez ^{106,107}, Derek W. Morris ⁴⁵, Thomas W. Mühleisen ^{15,16,33}, Robin M. Murray ¹⁰⁸, Jacob Nielsen⁵², Jan E. Nordvik¹⁰⁹, Lars Nyberg^{17,18,110}, Loes M. Olde Loohuis ¹¹¹, Roel A. Ophoff ^{111,112}, Michael J. Owen ⁴³, Tomas Paus ^{113,114}, Zdenka Pausova ^{20,114}, Juan M. Peralta ²¹, G. Bruce Pike ¹¹⁵, Carlos Prieto ¹¹⁶, Erin B. Quinlan ¹¹⁷, Céline S. Reinbold^{33,34,50}, Tiago Reis Marques ^{118,119}, James J. H. Rucker ¹²⁰, Perminder S. Sachdev ^{24,121}, Sigrid B. Sando^{69,122}, Peter R. Schofield ^{123,124}, Andrew J. Schork ^{125,126}, Gunter Schumann ¹¹⁷, Jean Shin ^{20,114}, Elena Shumskaya^{53,127}, Ana I. Silva ^{4,43,44}, Sanjay M. Sisodiya^{92,94}, Vidar M. Steen^{90,91}, Dan J. Stein ¹²⁸, Lachlan T. Strike ¹⁰², Ikuo K. Suzuki^{129,130,131}, Christian K. Tamnes ^{1,132,133}, Alexander Teumer ¹³⁴, Anbupalam Thalamuthu²⁴, Diana Tordesillas-Gutiérrez ^{36,135}, Anne Uhlmann³⁹, Magnus O. Ulfarsson ^{8,136}, Dennis van 't Ent^{12,22},

Marianne B. M. van den Bree^{43,71}, Pierre Vanderhaeghen ^{137,138,139}, Evangelos Vassos ^{108,140}, Wei Wen ²⁴,
Katharina Wittfeld ^{65,66}, Margaret J. Wright ^{102,141}, Ingrid Agartz^{85,86,133}, Srdjan Djurovic ^{2,90},
Lars T. Westlye ^{1,3,50}, Hreinn Stefansson ⁸, Kari Stefansson ^{8,9}, Sébastien Jacquemont ^{5,142},
Paul M. Thompson³² and Ole A. Andreassen ¹

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com